Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AAV, Adjudication, affirmed, Allied, ANVISA, argument, begun, biometric, Boston, branch, Brazil, Brazilian, capacity, charity, Clauser, CMS, Cumberland, depth, destruction, disaster, driver, dysferlin, dysferlinopathy, EEA, eudract, exceeded, gathered, heard, implicit, inseverable, instability, intervention, Jain, Komjathy, left, LinkerTM, microdystrophin, mission, Miyoshi, Noah, Northern, oppose, outbreak, pandemic, paper, partly, PCT, pressed, PULDYSA, reassessing, reconsideration, remanded, repair, ROU, staying, thereunder, unamortized, unconstitutional, uninsured, uninterrupted, vamorolone, viltolarsen, virtually, VP, water, weather, younger
Removed:
adjustment, Akashi, Alliance, approximated, ataluren, ataxia, Bldg, breakdown, cancelled, Cardero, center, closing, computer, conjunction, converted, correlated, cunnane, deirdre, deposit, depreciated, distinct, driven, ending, ESPP, fat, fraction, franchise, Friedreich, furniture, iii, leasehold, lesser, link, modality, recipient, recognizing, registering, remained, removed, retrospective, sixteen, SPV, Suite, thirteen, Treaty, unused, vast, Wave
Filing tables
Filing exhibits
Associated ATXS transcripts
ATXS similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
- 1)
- Registration Statement (Form S-1 Nos. 333-225410 and 333-225734) of Catabasis Pharmaceuticals, Inc., and
- 2)
- Registration Statement (Form S-3 No. 333-231441) of Catabasis Pharmaceuticals, Inc., and
- 3)
- Registration Statement (Form S-8 Nos. 333-206394, 333-210229, 333-216793, 333-223721, 333-229643) pertaining to the equity incentive plans of Catabasis Pharmaceuticals, Inc.;
of our report dated March 10, 2020, with respect to the consolidated financial statements of Catabasis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Catabasis Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 10, 2020
Consent of Independent Registered Public Accounting Firm